Sapient Capital LLC Boosts Stock Position in Johnson & Johnson $JNJ

Sapient Capital LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 104.9% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 101,237 shares of the company’s stock after purchasing an additional 51,822 shares during the period. Sapient Capital LLC’s holdings in Johnson & Johnson were worth $26,801,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in JNJ. Auto Owners Insurance Co increased its holdings in Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after buying an additional 69,108,368 shares during the period. Wellington Management Group LLP boosted its stake in Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Johnson & Johnson by 8.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock worth $3,575,255,000 after buying an additional 1,376,828 shares during the period. Deutsche Bank AG increased its position in shares of Johnson & Johnson by 8.5% in the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after acquiring an additional 1,225,676 shares during the period. Finally, Amundi raised its stake in Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after acquiring an additional 2,001,139 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ traded down $1.60 during trading hours on Thursday, reaching $256.85. 6,146,800 shares of the company were exchanged, compared to its average volume of 7,971,840. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market cap of $618.99 billion, a PE ratio of 29.76, a price-to-earnings-growth ratio of 2.50 and a beta of 0.21. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07. The stock’s 50-day moving average is $265.73 and its 200-day moving average is $248.93.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 11.54 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th were given a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s payout ratio is presently 62.11%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong earnings setup: Analysts are focused on JNJ’s September-quarter revenue, earnings, pharmaceutical growth and operating performance. The company has a history of exceeding estimates, while its latest quarter showed 6.6% year-over-year revenue growth and adjusted EPS above consensus. JNJ’s full-year 2026 EPS outlook is $11.60-$11.75. Johnson & Johnson Q3 earnings preview
• Positive Sentiment: Pipeline could support faster growth: Positive longer-term data for ICOTYDE in psoriasis and encouraging Phase 3 multiple-myeloma results for the Tecvayli-Talvey combination strengthen the case that JNJ can generate growth beyond its traditional defensive profile. Johnson & Johnson long-term growth outlook
• Positive Sentiment: Analyst and dividend support: Guggenheim reaffirmed a Buy rating with a $287 price target, while other coverage continues to highlight JNJ’s 64-year record of dividend increases. The company is viewed as offering more dependable cash generation than higher-yielding but financially weaker peers. Johnson & Johnson dividend outlook
• Neutral Sentiment: Valuation reflects quality: Commentary comparing JNJ with Pfizer argues that JNJ commands a higher earnings multiple because its earnings outlook is more stable and potentially stronger. That premium may support the shares, but it also leaves less room for disappointment if quarterly results or guidance fall short. Johnson & Johnson valuation comparison
• Negative Sentiment: Key risks remain: Investors continue to monitor biosimilar competition, slower MedTech growth and ongoing talc litigation. These issues could pressure future pharmaceutical sales, margins or investor confidence despite the company’s dividend record. Johnson & Johnson risks and dividend analysis

Analysts Set New Price Targets

A number of equities research analysts recently commented on JNJ shares. Citigroup lifted their target price on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday. Morgan Stanley increased their price target on Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research report on Thursday, July 16th. Johnson Rice restated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a report on Wednesday, July 15th. Finally, Scotiabank reissued an “outperform” rating and issued a $305.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $276.22.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,569 shares of company stock valued at $23,064,544 in the last 90 days. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.